From: Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal
Normal control (n = 27) | Episodic migraine (n = 99) | Chronic migraine (n = 44) | P-value | |
---|---|---|---|---|
Age | 34 (27–42) | 44 (31–49) | 39.5 (31–54) | 0.016 |
Female sex | 25 (92.6%) | 78 (78.8%) | 36 (81.8%) | 0.258 |
Migraine with aura | NA | 18 (18.2%) | 8 (18.2%) | > 0.999 |
Headache days/month | NA | 5 (2–10) | 27 (15–30) | < 0.001 |
Hypertension | 0 (0%) | 6 (6.06%) | 5 (11.36%) | 0.162 |
Diabetes | 0 (0%) | 0 (0%) | 1 (2.27%) | 0.237 |
Dyslipidemia | 0 (0%) | 6 (6.06%) | 5 (11.36%) | 0.162 |
Stroke | 0 (0%) | 1 (1.01%) | 1 (2.27%) | 0.670 |
Cardiac disease | 0 (0%) | 2 (2.02%) | 2 (4.55%) | 0.445 |
Current smoking | 0 (0%) | 6 (6.06%) | 5 (11.36%) | 0.162 |
Fibromyalgia | 0 (0%) | 1 (1.01%) | 2 (4.55%) | 0.250 |
Depression | 0 (0%) | 4 (4.04%) | 12 (27.27%) | < 0.001 |
Anxiety disorder | 0 (0%) | 1 (1.01%) | 8 (18.18%) | < 0.001 |
Panic disorder | 0 (0%) | 2 (2.02%) | 3 (6.82%) | 0.180 |
Preventive medication | 0 (0%) | 19 (19.19%) | 22 (50%) | < 0.001 |
TCA | 0 (0%) | 13 (13.13%) | 18 (40.91%) | < 0.001 |
Beta-blocker | 0 (0%) | 15 (15.15%) | 15 (34.09%) | 0.001 |
CCB | 0 (0%) | 12 (12.12%) | 13 (29.55%) | 0.002 |
Antiepileptic drugs | 0 (0%) | 3 (3.03%) | 11 (25%) | < 0.001 |
ARB | 0 (0%) | 2 (2.02%) | 1 (2.27%) | 0.745 |